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Cell-based medicinal products (CBMPs) are rapidly gaining importance in the treatment of life-threatening
diseases. However, the analytical toolbox for characterization of CBMPs is limited. The aim of our study was
to develop a method based on flow imaging microscopy (FIM) for the detection, quantification and character-
ization of subvisible particulate impurities in CBMPs. Image analysis was performed by using an image classi-
fication approach based on a convolutional neural network (CNN). Jurkat cells and Dynabeads were used in
our study as a representation of cellular material and non-cellular particulate impurities, respectively. We
demonstrate that FIM assisted with CNN is a powerful method for the detection and quantification of Dyna-
beads and cells with other process related impurities, such as cell agglomerates, cell-bead adducts and debris.
By using CNN, we achieved a more than 50-fold lower misclassification rate compared with the use of output
parameters from the FIM software. The limit of detection was ~15 000 beads/mL in the presence of
~500 000 cells/mL, making this approach suitable for the detection of these particulate impurities in CBMPs.
In conclusion, CNN-assisted FIM is a powerful method for the detection and quantification of cells, Dynabeads
and other subvisible process impurities potentially present in CBMPs.
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Technological advancements in the past decades have profoundly
revolutionized the area of biotherapeutics [1]. Cell-based medicinal
products (CBMPs), an important category of medicinal products
based on cells or tissues, are rapidly gaining significance because
they can serve as an effective cure for patients where no other treat-
ment option is available. Examples of CBMPs include stem cells,
(genetically modified) T cells and (antigen-loaded) dendritic cells [2].
More than a thousand clinical trials with CBMPs are completed or
underway (as of January 2020, www.clinicaltrials.gov), and regula-
tory agencies are expecting an increasing number of market appro-
vals in the coming years [3]. A recent breakthrough in this field was
the approval of two genetically engineered T cells (chimeric antigen
receptor [CAR] T cells) in the United States in 2017 and in Europe in
2018. Despite their clinical success, challenges with respect to
manufacturing and quality control (QC) must be faced to make
CBMPs commercially viable [4].Manufacturing of CBMPs, such as the current generation of CAR T
cells, is a much more complex and labor-intensive process compared
with the production of classical protein-based biologics [2,5]. For
instance, the production of CAR T cells involves collection of cells
from the patient via leukapheresis, ex vivo transduction with a viral
vector, encoding the CAR transgene, T-cell activation and expansion,
formulation, fill and finish, storage and QC before intravenous infu-
sion. Moreover, the manufacturing processes involve the addition of
raw materials, such as media, vector, cytokines or antibody-coated
magnetic beads. Some of the raw materials can diminish the safety of
the final drug product and are considered as impurities. An example
are monoclonal antibody-coupled magnetic beads, which must be
removed from the process to acceptable levels and need to be mea-
sured as part of product QC testing [6].
Most CBMPs consist of a suspension of living cells with a size typi-
cally between 10 and 30mm. Lymphocytes, including T cells, are gen-
erally smaller in diameter and can range from 7 to 18mm in diameter
[7]. Therefore, only large-pore filters (70-mm pore size) can be used
during manufacture. Such filtration is not capable of removing partic-
ulate impurities within the micron and submicron size range. Ineffec-
tive removal of these particulates, derived either from raw materials
or from manufacturing processes, may potentially lead to adverse
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glass particles, metal particles, fibers) may result in occlusion of small
capillaries of the circulatory system [9]. Moreover, proteins can
adsorb to such non-proteinaceous particles, which may result in
unwanted immunogenicity [10]. Furthermore, micro- and submi-
cron-sized proteinaceous particles, which may originate from cells or
cell culture medium, have been shown to increase the risk of
unwanted immunogenicity [11]. In addition, necrotic cells and cell
debris tend to have a smaller diameter compared with healthy cells
[12]. Therefore, monitoring the size of cells and other particulate
matter may aid in assessing the quality of CBMPs.
For CBMPs, because of their particulate nature, it is challenging to
fulfill specific pharmacopeial testing requirements. The compedial
specifications set limits for the number of visible and subvisible
(micrometer-sized) particles (USP <790> and <788>, respectively)
in injectable drug products [13,14]. The current pharmacopeial meth-
ods include visual inspection and light obscuration or microscopic
particle count test for visible and subvisible particles, respectively.
Visual inspection may not consistently and reliably detect visible par-
ticles in CBMPs because these products may be highly opalescent and
viscous due to the high cell concentration (e.g., 105107 cells/mL).
Furthermore, CBMPs are often supplied as a single-dose, low-volume
(microliter to milliliter range) sterile suspension in a (cryo)vial, which
has a relatively thick wall, making visual inspection difficult. In addi-
tion, subvisible particle analysis by light obscuration is challenging
because light obscuration cannot differentiate cells from foreign and
particulate impurities. Despite the preceding considerations, from a
quality, safety and potentially efficacy perspective, it is prudent that
subvisible particles in CBMPs are adequately tested [15].
Flow imaging microscopy (FIM) techniques have been widely
used for the characterization of subvisible particles in protein-based
drugs [16]. Using these techniques, one can derive concentration,
size and morphological parameters of particles within the microme-
ter size range frommicroscopic images. Different particle populations
can be discriminated based on particle structure and appearance
[17,18]. Recently, FIM has been applied to study cell viability and con-
fluency in cell culture as well as quality of CBMPs [12,19-21]. How-
ever, comprehensive particle characterization reaches a limit when
using the morphological parameters derived from the instruments’
operating software because of the complexity of CBMPs, which may
consist of multiple particulate populations of highly heterogeneous
morphologies.
Deep learning for image analysis is an alternative approach, offer-
ing more insight into the collected data and potentially allowing for a
better discrimination of particle populations. The increasing comput-
ing power and advancements in algorithms for pattern recognition
have made the deep learning methods, such as convolutional neural
networks (CNN), useful tools in many fields, including the biophar-
maceutical industry [22]. Deep learning refers to a multilayered neu-
ral network consisting of hidden layers as well as an input and
output layer. It can be exceptionally effective in extracting intricate
structures in raw (pre-processed) data and recognition of representa-
tive features that allow categorization of images with minimum error
[23]. For example, protein aggregates formed upon different stress
methods were imaged by using FIM and successfully discriminated
with the aid of CNN, based on the distinct particle morphology result-
ing from each stress method [24]. In the area of cell biology, CNN
have brought microscopy to a new level, where features such as the
type of intracellular structures or the cell cycle and type of cells, pre-
viously requiring immunohistochemistry, can now be recognized
without fluorescent labeling [25].
In our study, we used a flow imaging microscope, FlowCam, to
collect images of subvisible particulate matter in T-cell samples and
developed an automated image classification method based on CNN
for the analysis of the raw images (henceforth referred to as Flow-
Cam-CNN). As a model system, we used suspensions of Jurkat cells(816 mm in diameter) and CD3/CD28 Dynabeads (4.5 mm in diame-
ter); the latter are commonly used for T-cell activation and purifica-
tion. We show that the developed FlowCam-CNN method enables
the detection, quantification and characterization of process-related
particulate impurities (e.g., Dynabeads, cell-bead adducts) as well as
product-related particulates (e.g., cells, cell agglomerates and debris).
Materials and Methods
Materials
T-cell leukemia cells (Jurkat, Clone E6-1, ATCC TIB152TM) were
provided by Leiden University Medical Centre (LUMC) as frozen 1-mL
aliquots at a total cell concentration of 107 cells/mL, and were stored
at 140°C in the freezer before use. The Jurkat cells were formulated
in high-glucose RPMI 1640 (RPMI medium; ThermoFisher, Waltham,
MA, USA) supplemented with 10% fetal bovine serum (FBS; Life Tech-
nologies, Eugene, OR, USA) and 10% dimethyl sulfoxide (DMSO) (Life
Technologies). Dynabeads Human T-Activator CD3/CD28 for T Cell
Expansion and Activation, and low-protein-binding collection tubes
were purchased from ThermoFisher. Sterile 5-mL Eppendorf tubes
were purchased from VWR (Ismaning, Germany).
Sample preparation
Jurkat cells used in this study as model T cells were thawed and
freshly prepared in RPMI medium before analysis. Frozen cell aliquots
were thawed at 36°C and resuspended in ~40 mL of RPMI medium. To
remove residual FBS and DMSO, the cell suspension was centrifuged
at 300 rcf for 10 min at 20°C. The supernatant was removed, and the
pellet was resuspended in 10 mL of RPMI medium, unless otherwise
stated. The mean concentration of (live and dead) cells was 477 188
§ 85 914/mL with a mean viability of 81% § 9% (n = 8) as determined
by hemocytometry (described subsequently), unless otherwise
stated. Cell-containing samples were measured up to 4 h post-thaw-
ing, during which the cell viability was not affected (data not shown).
Dynabeads were diluted to an intermediate stock concentration of
106 beads/mL (based on the dilution factor of the nominal Dynabead
concentration) in RPMI medium and stored at 28°C for up to 1
month. The required volume of the intermediate stock was added to
cell samples to reach the desired Dynabead concentrations. Reference
concentration of Dynabeads stated in the Results section is the
expected concentration of Dynabeads in the sample derived from
dilution calculations and the original bead concentration stated by
the manufacturer. It must be noted that the manufacturer does not
use FlowCam for quantification of Dynabeads; therefore, a systematic
deviation between reference concentrations and measured concen-
trations should be anticipated.
Hemocytometry
Cell viability and total cell concentration were determined by
using a Bright-Line hemocytometer glass (Merck, Darmstadt, Ger-
many) and an Axiostar Plus microscope (Zeiss, Jena, Germany) with
10 £ magnification (Zeiss). The washed cell suspension was diluted
twofold with a sterile-filtered 0.4% Trypan Blue solution (Merck,
Darmstadt, Germany). Next, 10 mL of the mixture was placed in the
hemocytometer and at least 100 cells were counted (both viablenot
stained, and nonviablestained cells), following the manufacturer’s
recommendations.
Flow imaging microscopy
For characterization of micron-sized particles, a FlowCam 8100
(Fluid Imaging Technologies, Scarborough, ME, USA) equipped with
an 80-mm flow cell and a 10 £ objective was used. The instrument
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sis was performed by using a flowrate of 0.18 mL/min, and the detec-
tion thresholds were set to 17 for dark pixels and 15 for light pixels.
Images were taken with a high-resolution CMOS camera
(1920 £ 1200 pixels) at 27 frames/s. In total, a sample volume of
0.5 mL was analyzed with an efficiency of approximately 70% (i.e.,
the measured sample volume was ~0.35 mL). Cleaning steps between
sample measurements involved thorough flushing of the flow cell
with 2% Hellmanex III and highly purified water. Diameters are
reported as equivalent spherical diameter (ESD), and filters were not
applied for imaging pre-processing. Samples were measured in tripli-
cate or sextuplicate unless otherwise stated.
Samples measured within this study contained particles of five
distinct populations: single cells, doublet cells, Dynabeads, adducts
(defined as a combination of at least one bead with at least one cell)
and debris (any other cellular and non-cellular types of particles). For
reporting the total determined concentration of cells, we summed
the counts of single cells, adducts and 2 £ doublet cells. The deter-
mined concentration of Dynabeads in measured samples was derived
from the summed counts of Dynabeads and adducts.
Generation of particle images for population discrimination
Establishment of threshold values and training of the CNN was
performed on manually selected images (40004500) of each popu-
lation class, which was shown to be sufficient for training our modelFigure 1. Clustered morphological parameters used to discriminate the five particle popu
accompanying numbers show the order in which the separation of particle populations was cto a reach high classification accuracy (>0.99). To facilitate the selec-
tion process for debris and adducts, samples with elevated numbers
of the respective particles were generated prior to FlowCam analysis.
Samples enriched in particles representing debris were obtained by
submitting freshly resuspended (cryoprotectant free) cell suspen-
sions to two freeze-thaw cycles (-14036°C). Samples with high
numbers of adducts were generated by incubation of cells (~500 000
cells/mL) in presence of Dynabeads in a number ratio of 1:1 for 1.5 h
at 37°C and 5% CO2.
Development of morphological filters for FlowCam
The VisualSpreadsheet software of the FlowCam system outputs
30 morphological parameters for each detected particle within the
measured sample. Five of these available parameters—intensity,
sigma intensity, convexity, compactness and aspect ratio—were
found to have the highest resolving power for particle populations.
Values of particle properties for each population class were further
clustered into 1-mm sized bins and are presented in box plots
(Figure 1). For the development of threshold values used to assign
each particle to its class, a similar approach as previously reported for
the discrimination of silicone oil and protein aggregate particles was
used [17]. Briefly, a stepwise approach was followed, as described in
the following paragraphs.
First, Dynabeads and adducts were separated from cells (singlets
and doublets) and debris, based on mean particle intensity values.lations (see text) by using the output data from the FlowCam software. Arrows with
arried out.
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transparent” particles (Dynabeads and adducts) and of the 90th quar-
tile of “highly transparent” particles (cells and debris) were calcu-
lated as a function of size. For size regions in which only one
population was present, the cutoff threshold was adjusted manually
below or above of the 95th quartile parameter value. Furthermore, a
4-degree polynomial function was fitted to these points from 3 to 35
mm and tested particles of a certain diameter falling above or below
the threshold value set were assigned to either group.
Second, threshold values for compactness, convexity and sigma
intensity were derived in a similar manner, which allowed for sepa-
ration of adducts from Dynabeads and cells from debris. For separa-
tion of single cells and doublet cells, the aspect ratio parameter was
applied. Therefore, each tested particle must have fulfilled at least
three criteria to be assigned to a specific population class. All particles
with a diameter below 3mmwere assigned to the debris population.
Deep convolutional neural networks
The VGG-19 architecture was used as the foundation for our CNN
[26]. This architecture includes 19 convolutional (weight) layers and
can capture a large range of visual object features. The network
weights are optimized by reformulating convolutional layers as
learning residual functions, taking the input to layers as reference.
The VGG-19 network used in our studies has been pre-trained on the
open source ImageNet dataset found in [27]. By fine-tuning only the
last two fully connected layers, the feature complexity of the pre-
trained model can be optimized for the particle classification task.
For fine-tuning the image dataset was split into test, validation and
training sets at a 0.8, 0.1 and 0.1 ratio, respectively. Such division of
the dataset was aimed to maintain the classes balanced and so the
fine-tuning would not be biased toward a specific class. The deep
learning model was fine-tuned with 30 epochs with the Adam opti-
mization algorithm. The machine learning model was implemented
in the Keras (2.2.4)-Tensorflow (1.13.1) Python (3.7.3) library and ran
on a Nvidia Turing GPU with 11 GB of VRAM. A simplistic workflow
for image analysis by using CNN is presented in Figure 2.
Data analysis
Statistical analysis of data was performed in Origin 2016 (Origin-
Lab Corporation, Northampton, MA, USA). Box plots represent the
distribution of data where central rectangles span from the first to
the third quartile and whiskers range from the 5th up to the 95thFigure 2. Illustration of the CNN work flow. First, a collection of 40004500 images from
each particle class was manually selected for training with the VGG-19 network. During
training, kernels of weights in the two last layers of our network are updating weight
parameters and extracting representative image descriptors based on the input data. Once
training is completed, the network can be used to predict particle classes of new (not used
during training) images. Output is given as a probability of an image assigned to the stated
class. A detailed description of the VGG-19 network can be found in Simonyan et al. [26].percentile values. For comparison of mean values, a two-sided Stu-
dent’s t-test with a = 0.05 (95% confidence interval) was used.
The limit of detection (LOD) and limit of quantification (LOQ) were
determined by using values of the entire tested range for Dynabeads,
where six measurement replicates were performed for each bead con-
centration. LOD and LOQ were calculated by using Eqs. 1 and 2 [28]:
LOD ¼ 3:3  sð Þ=S ð1Þ
LOQ ¼ 10  sð Þ=S ð2Þ
where s is the standard error of the y-intercept, and S is the slope of
the linear regression line.Results
Identification of particle populations in cell suspensions
Analysis of cell suspensions supplemented with Dynabeads was
performed by using FlowCam and representative examples of gener-
ated images of the five distinct particle populations are shown in
Figure 3. Besides single cells, debris and Dynabeads, we observed a
noticeable number of images with two captured cells (doublet cells)
as well as cells with one or more adjacent Dynabeads (adducts). Parti-
cle size distributions of samples containing cells (without beads),
Dynabeads (without cells) and a mixture of cells and Dynabeads are
shown in Figure 3. Samples containing cells showed a broad peak
between 10 and 16 mm, representing the Jurkat cells (Figure 3A).
Furthermore, a sharp peak at the lower size limit of detection
was observed and assigned to debris. Dynabeads showed a
bimodal peak with maxima at 3.5 and 6.0 mm (Figure 3B). These
values represent the measured size of beads from in-focus (sharp)
and out-of-focus (blurred) images and are close to the mean bead
diameter of 4.5 mm stated by the manufacturer. Particle size dis-
tributions of mixtures of Dynabeads and cells looked like a sum-
mation of the cells and the beads (Figure 3C). Although these
samples were found to contain adducts (see Figure 3, top panel),
which obviously were not present in the other samples, the num-
ber of adducts was relatively small and did not substantially
affect the overall size distribution.Morphological parameters for particle classification
For beads suspended in the RPMI medium, a linear relation was
found between themeasured Dynabead concentration and the expected
Dynabead concentration derived from the dilution factor, with a linear-
ity of R2 = 0.95 (supplementary Figure 1A), based on the selected mor-
phological parameters with the FlowCam software (cf. Figure 1).
Measurements of beads in the presence of cells (~500 000 total cells/mL
by using a hemocytometer) resulted in a similar linear correlation
(R2 = 0.98). However, unexpectedly high numbers of unclassified par-
ticles (i.e., particles with morphological parameters not falling into any
of the five classes) were found. The coefficient of variation for measured
concentrations of Dynabeads in presence of cells was noticeably higher
compared with the control samples. Additionally, the recovery of Dyna-
beads in cell suspensions at the lowest three reference concentrations
was >100%, suggesting a number of debris and other particles were
misclassified as Dynabeads (or adducts) when using this approach.
Dynabeads suspended in RPMI medium showed recovery rates from
25% (lowest Dynabead concentration) up to 85% (highest Dynabead
concentration) (data not shown). Altogether, using the morphological
particle parameters output from the FlowCam software resulted in a
good correlation between detected concentrations and reference con-
centrations of Dynabeads. However, the high numbers of unclassified
particles and the noticeable variation in determined particle concentra-
tions illustrate the friability of this classification approach.
Figure 3. Representative images of each population class obtained by using FlowCam (top). All images were enlarged for presentation and actual size is not represented. Particle
size distributions of samples containing (A) Jurkat cells (375 000 cells/mL), (B) Dynabeads (68 000 beads/mL) and (C) Jurkat cells + Dynabeads (bottom).
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Because accurate discrimination of particle populations, present
in cell suspensions, was not satisfactory with conventional morpho-
logical filters, we applied CNN for analysis of raw FlowCam images.
The fine-tuned FlowCam-CNN model with the pre-selected datasets
(see methods section above and Figure 2) was used to classify on
average 140 000 images per sample into individual particle classes.Detection and quantification of Dynabeads
In contrast to the results based on the morphological particle
parameters output described above, FlowCam-CNN analysis resulted
in classification of all particles present cell suspensions
(500 000 cell/mL counted by using a hemocytometer) with or with-
out Dynabeads (Figure 4). Linearity over the entire tested Dynabead
concentration range was>0.95 for both sample sets, and slope values
were ~0.8. Samples containing cells and >50 000 beads/mL had
recovery values >80% and a coefficient of variation below 15%. The
relative error of the determined bead concentration was apparently
random and showed a uniform distribution around 0 for samples
with cells, except for the lowest bead concentrations measured (data
not shown). Dynabeads suspended in cell-free RPMI medium at refer-
ence concentrations <60 000 beads/mL showed lower recoveries
compared with samples containing cells, which exceeded a recovery
rate of 75% within the tested range. The coefficient of variation of
determined Dynabead concentrations was >10% for samples with
<50 000 beads/mL and <10% for the higher tested bead concentra-
tions. Therefore, the optimal Dynabead concentration for quantifica-
tion of beads by using FlowCam-CNN was determined to be from
»45 000 beads/mL to at least 200 000 beads/mL.
The FlowCam method assisted with automated image classifica-
tion (FlowCam-CNN) was examined in alignment with the ICH Q2
(R1) guideline for validation of analytical procedures. Accuracy, preci-
sion, LOD, LOQ and linear relationship for Dynabeads detection in
absence and presence of cells were evaluated and the results are pre-
sented in Table I.
The LOD and LOQ were ~15 000 and 45 000 beads/mL, respec-
tively, whereas slightly higher values were found for Dynabead sus-
pensions in absence of cells.Accuracy and precision (repeatability) were calculated for Dyna-
bead concentrations above the LOQ, and the values present averages
of two intra-day sets of triplicate measurements. Accuracy was deter-
mined as the recovery of spiked in Dynabeads with respect to the ref-
erence concentrations (Recovery%). Accuracy was found to be
substantially lower for beads in absence of cells at reference concen-
trations <50 000 beads/mL. Above this concentration, the presence
of cells did not have an impact on the accuracy of quantification. Fur-
thermore, precision of Dynabeads concentration determination was
evaluated as the coefficient of variation (CV%) and overall values
were <10%.Characterization of cellular particulate matter
In addition to developing a method for characterization of non-
cellular particles, we aimed to quantify debris (a potential impurity)
as well as cells and adducts.
The tested concentrations of Dynabeads in Jurkat cell suspensions,
presented in Figure 4, were studied at a constant cell concentration
(385 711 § 59 337 cells/mL as determined with FlowCam). The pres-
ence of Dynabeads did not have a significant impact on the number
of quantified total number of cells (t-test, two-sided, P > 0.17; sup-
plementary Figure 2A). Moreover, the numbers of detected particles
classified as debris in cell samples without and with Dynabeads were
highly comparable. Furthermore, as expected, the number of
detected adducts increased with higher concentrations of beads pres-
ent in cell samples (supplementary Figure 2B,C).Misclassifications
The misclassification rate was calculated in an indirect manner
because of the large number of acquired images per measurement
(>100 000 per measurement). Debris particles were present in all
measured samples (Dynabeads and cell suspensions); therefore, we
did not consider the misclassification rate for this population.
Figure 5A represents the rates of erroneously detected cells (singlets,
doublets and adducts) and of unclassified particles within Dynabead
suspensions of different reference concentrations. Figure 5B presents
the error rates of detected Dynabeads and adducts as well as unclas-
sified particles within cell only suspensions at a cell concentration of
~375 000 cells/mL (as measured by FlowCam). In both cases, the
Figure 4. Presented data on classified Dynabeads (DB) by using CNN. (A) Determined concentration of Dynabeads in a concentration series of Dynabeads suspended in RPMI
medium (DB ctrl, gray) and in Jurkat cell suspensions (DB + cells, black). (B) Recovery (left y-axis, black) and corresponding coefficient of variation (CV; right y-axis, red) of Dyna-
beads in RPMI medium (open squares) and Jurkat cell suspensions (closed squares). Error bars represent the standard deviation of mean values of six replicates. The coefficient of
variation values (%) were calculated from the six replicate measurements.
Table I
Parameters determined by FlowCam-CNN based on mean values of two inter-
day triplicate measurements.




Accuracy (Recovery%) 86.9 § 5.4 80.5 § 12.6
Precision (CV%) 4.7 § 0.9 8.0 § 3.2
LOD (beads/mL) 15 229 13 661
LOQ (beads/mL) 46 149 41 396
Linearity (R2) 0.988 0.959
The LOD and LOQ were deteremined for Dynabead concentrations tested in the
study and presented in Figure 4. Accuracy and precision were determined
for Dynabead concentrations above the LOQ. Cell concentration was
~375 000 cells/mL.
Figure 5. Error rates of particles classified as (A) cells or adducts in Dynabead suspen-
sions with different Dynabead target concentrations (x-axis) and (B) Dynabeads and
adducts in cell suspensions at 375 000 cells/mL (as determined by using FlowCam).
Error rates are based on misclassified particles by using CNN (filled bars), and on mis-
classified and unclassified particles by using particle morphological parameters (empty
bars). Error bars are standard deviations of mean values of six replicates.
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essed by using CNN. Furthermore, the error rate was independent of
the spiked-in amount of Dynabeads, as the fraction of misclassified
particles was similar for each of the tested concentration of beads in
cell suspensions. Particles analyzed by using morphological parame-
ters showed a much higher inaccuracy and unclassified fraction,
which is reflected by the relatively high error rates (up to 50-fold
higher compared to CNN).
Figure 6 presents the probability distribution, as determined by
deep learning classification, of particle images classified as Dyna-
beads. Particle images were collected during FlowCammeasurements
of Dynabeads (80 000 beads/mL) in presence and absence of cells. In
our classification network, the Softmax regression function was inte-
grated, which is an activation function converting calculated weightsFigure 6. Probability distribution (binned in units of 0.01) of classified particle images
determined by FlowCam-CNN for Dynabead suspension (filled) and cell suspension
suplemented with Dynabeads (empty) at a concentration of 80 000 beads/mL. Repre-
sentative images are shown with their asssgned probability of belonging to the Dyna-
bead class.
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<0.2. For the sample with suspended Dynabeads in RPMI medium,
the vast majority of images classified to the bead class had a probabil-
ity equal to 1, which confirmed that the network made the assign-
ment with very high confidence. Moreover, this high confidence was
not impacted by the presence of cellular material in the sample,
as similar counts of beads with a probability of 1 were found in sam-
ples containing Jurkat cells. In conclusion, these data demonstrate
that image classification by using FlowCam-CNN is highly accurate.
Effect of cell concentration on measurement
The impact of the Jurkat cell concentration on the quantification of
Dynabeads in cell suspensions by FlowCam-CNN was investigated,
and the results are presented in Figure 7. Dynabeads spiked into sam-
ples with cell concentrations up to »500 000 cells/mL (as determined
by using a hemocytometer) resulted in similar measured bead con-
centrations in presence of cells. At the highest tested cell concentra-
tion (900 000 cells/mL), we observed an underestimation of detected
beads at reference Dynabead concentrations of 50 000 and
100 000 beads/mL. Such an underestimation was not observed for
the lowest tested Dynabead concentration (20 000 beads/mL). Fur-
thermore, control samples showed lower Dynabead recoveries com-
pared with samples with cell suspensions.
Discussion
Characterization of cellular and non-cellular (i.e., foreign) particu-
late matter in CBMPs is important to guarantee a good quality and
safe product [8]. Additionally, with the limited time available for ana-
lytical testing of some cell products, straightforward, rapid and com-
prehensive methods are urgently needed [5].
In this study we used a model system containing Jurkat cells, serv-
ing as a surrogate for T cells, such as CAR-T cells [29], and Dynabeads
CD3/CD28, serving as a representative potential process-related par-
ticulate impurity in CAR-T cell products [30]. These super-paramag-
netic beads coupled to CD3 and CD28 monoclonal antibodies are
used in the production of CBMPs [31]. However, their removal before
the final formulation step remains difficult [32]. More important,Figure 7. Determined concentration of Dynabeads in RPMI medium (control; filled bars) and
by using hemocytometry) were tested with reference concentrations of Dynabeads of (A) 20
tions of triplicate measurements of Dynabeads in cell suspensions and of nonuplet measuremtaking into consideration reports on the potential toxicity of Dyna-
beads [30], methods showing effective and consistent removal of
these impurities in the manufacturing process are required. There-
fore, in our study, we assessed the feasibility of FIM for the discrimi-
nation of Dynabeads and cells, and for the assessment of the
Dynabead concentration. We hypothesized this should be possible
because Dynabeads differ in size and morphological properties from
T cells. It must be noted that the full production protocol, where
beads are present in cell medium for days or weeks, was not mim-
icked here; Dynabeads were spiked into cell suspensions shortly
before analysis. Therefore, monitoring the stability of beads in the
suspension and their interactions with cells over time was beyond
the scope of this study.
The FIM-based method may offer advantages for characterizing
CBMPs because it is a high-throughput technique capable of rapid
measurements of high sample numbers without laborious prepara-
tive steps. The two most commonly used FIM systems are FlowCam
and Micro-Flow Imaging (MFI). Previously, it has been shown that
FIM techniques have the potential in determination of cell concentra-
tion and viability [12]. For our study, FlowCam was chosen because of
its capability of recording images of high quality and its high accuracy
and precision in particle concentration determination [33]. A down-
side of the FlowCam technique can be the relatively inaccurate parti-
cle sizing, resulting from a narrow depth of focus within the field of
the imaging system. As a result, particles of a homogenous diameter
may show a bimodal distribution [34], which was also observed in
the present study (Figure 3). Accurate sizing was not of key impor-
tance in our study. However, in-focus and out-of-focus images should
both be assigned to the same particle class, implying an increase in
complexity of the classification process.
The verification of viability and total concentration of cells used in
our study was performed by using a hemocytometer. As shown in
previous studies [12,21], cell concentrations determined by using
FlowCam were lower compared with manual counting, and in our
case the difference was ~20%. Furthermore, the concentration of
Dynabeads detected by FlowCam deviated from the reference con-
centrations stated by the manufacturer, that is, the recovery was
always <100% especially for Dynabeads at lower concentrations.
This, however, can most likely be ascribed to a loss of beads duringcell suspensions (empty bars). Three different cell concentrations (x- axis; determined
000, (B) 50 000 and (C) 100 000 Dynabeads/mL. Error bars represent standard devia-
ents of Dynabeads in RPMI medium.
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Counter analyzer (method used by the manufacturer for quantifica-
tion) showed similar results (data not shown). Moreover, preliminary
studies showed a significant impact of used lab disposables (e.g., low-
protein binding materials, volume-to-surface ratios) on the deter-
mined concentration of Dynabeads. The high affinity of the antibody
coated beads to surfaces resulted most probably to adherence of
Dynabeads to polypropylene tubes and tips used for sample handling.
Interestingly, a more consistent and higher recovery rate was
observed for Dynabeads in presence of cells compared to Dynabeads
in cell-free RPMI buffer (control) over the measured concentration
range. In particular, a pronounced loss of beads at low concentrations
(<60 000 beads/mL) was observed in our cell-free control samples,
resulting in a recovery below 50%. Such high losses of Dynabeads
were not observed in the cell-containing samples, in which most
likely debris and other cell-related materials occupied free surfaces
and competitively decreased bead adsorption. Because the bead-to-
T-cell ratio is critical for T-cell activation or purificiation [35], bead-
preparative steps where dilutions in cell-free media are involved
should be carefully considered to reach the desired bead concentra-
tion and assure a consistent manufacturing process.
When using FIM, a capable demarcation approach is required for
accurate quantification of specific particle populations found within
highly heterogeneous samples. Output parameters by the instruments’
operating software can be helpful in discriminating particles based on
morphology but may be prone to high error rates [18]. The uniformity
of Dynabead images resulted in similar values of each particle parame-
ter and developed filters had close to no misclassifications and 5% of
unclassified particles for Dynabead-only samples. However, the mor-
phological nature of cells, cell aggregates and debris is highly heteroge-
neous and the distribution of each of these particle parameters was
highly disperse (Figure 1). Furthermore, adducts and cells had in many
cases interchangeable values for most particle parameters. The error
rates (misclassifications and unclassified particles) for images containing
only cells were approximately 20% with datasets used for developing
morphological filters. Error rates for cell and Dynabead suspensions
were ~10% with testing datasets. The lack of a high capability in discrim-
ination of different particle population groups by using morphological
parameters prompted us to use an automated image classification
method based on CNN.
Compared with other machine learning techniques, deep learning
is straightforward to use and achieves high accuracies with minimal
refinements to the network layers [22]. The high performance of neu-
ral networks is in most cases based on large datasets to train the net-
works. For successful training of an entire CNN, such as VGG-19,
several million labeled images per class are required. Although FIM
techniques are well suited for applications where comparably large
numbers of images can be collected within a relatively short period
of time and with low sample consumption, cleaning and labeling a
high-quality training dataset remains a challenge. Because the pre-
trained VGG-19 was able to efficiently differentiate features on the
ImageNet dataset, fine-tuning of the last two fully connected layers
by using a relatively small number of labeled FlowCam images
resulted in a powerful CNN for differentiation and quantification of
Dynabeads. The misclassification rate was significantly reduced with
the CNN and was only 0.2% for cell samples spiked with Dynabeads.
FlowCam-CNN was capable of quantifying a wide concentration
range of Dynabeads in cell suspensions, demonstrating a large
dynamic range. Furthermore, the high precision (CV% < 5%) in deter-
mination of Dynabead concentration in cell suspensions above the
LOQ presents this method as a robust approach for quantification of
process-related particulates.
The determined total cell and debris concentration was not affected
by the number of Dynabeads spiked into the suspension (supplemen-
tary Figure 2). As expected, the number of detected adducts increased
with increasing concentration of Dynabeads in the sample because ofthe higher probability of beads interacting with cells. Furthermore, a
concentration of 500 000 cells/mL showed to have no impact on the
quantification of Dynabeads in cell suspensions. However, at the high-
est cell concentration tested, we observed a clear decrease in recovery
of Dynabeads, which were spiked to a target concentration 50 000 and
100 000 beads/mL. This loss in recovery was not observed for the low-
est Dynabead concentration of 20 000 beads/ml. A possible explana-
tion could be the approach for counting Dynabead(s) attached to a
single cell. Cases in which a particle was classified as “adduct” were
considered to consist of a single cell and a single Dynabead, which was
true in the majority of cases. However, with increasing number of cells
or Dynabeads, the probability of capturing a cell with two or more
adhering Dynabeads per image becomes higher. Therefore, the under-
estimation of Dynabeads could have been related to the inaccurate
counting of beads in dense cell populations.Conclusions and Outlook
In our study, we developed a reliable method based on FIM cou-
pled with CNN for detection, characterization and quantification of
relevant particulate impurities, specifically Dynabeads. We showed
that small amounts of Dynabeads can be detected in cell suspensions
and a high precision in counting is achieved if the bead concentration
is above the determined LOQ. Moreover, cells and cellular impurities,
such as cell aggregates and adducts, can be easily classified by using
CNN. Quantification of these particles can assist in monitoring
manufacturing processes of CBMPs and assist in process and product
characterization, such as stability testing.
Further work is being carried out to enhance the capabilities of the
method for other cell lines, the identification of multiple beads
adhering to cells, as well as to characterize other populations of par-
ticulates potentially present in CBMPs, such as leachables, extract-
ables and beads used as carriers for the ex vivo expansion of adherent
cells. In addition, further evaluation of the presented method by
using orthogonal methods could endorse the results obtained from
the currently opaque processing algorithm, such as CNN [36]. This
would increase confidence and understanding of FlowCam-CNN, pre-
sumably supporting in-process and QC analyses at first, and poten-
tially becoming a critical release test. Currently, we are not aware of
other methods with similar performance and we believe that CBMP
development can benefit from FlowCam-CNN in its current state.Funding
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